Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | ACLY | P53396 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7683159 | 0.85 | SMN1; SMN2 (0.46) | MEN1KMT2AACLYSMN1; SMN2TSHR | |
| SCHEMBL7691842 | 0.80 | C5AR1 (0.57) | MEN1KMT2AACLYC5AR1 | |
| SCHEMBL7556650 | 0.79 | TSHR (0.49) | MEN1KMT2AACLYSMN1; SMN2TSHR | |
| SCHEMBL7685316 | 0.77 | USP2 (0.37) | MEN1KMT2ATMEM97SIGMAR1C5AR1 | |
| SCHEMBL6244108 | 0.76 | KMT2A (0.52) | MEN1KMT2ASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL27975616 | 0.76 | KDM4E (0.47) | ACLYSMN1; SMN2TSHRKDM4EALDH1A1 | |
| SCHEMBL6245225 | 0.76 | KMT2A (0.51) | MEN1KMT2ASMN1; SMN2TSHRKDM4E | |
| SCHEMBL7685261 | 0.76 | POLB (0.48) | MEN1KMT2ATMEM97SIGMAR1SMN1; SMN2 | |
| SCHEMBL7689766 | 0.75 | SMN1; SMN2 (0.45) | MEN1KMT2AACLYSMN1; SMN2TSHR | |
| SCHEMBL6245866 | 0.74 | HSD17B10 (0.44) | MEN1KMT2ASMN1; SMN2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045551-A1 | 4-benzoyl isoxazoles derivatives and their use as herbicides | MUSIL TIBOR (GB) | 2002-04-18 | — | — | US | disclosed |
| US-6323155-B1 | EXCELLENT LEVEL OF HERBICIDAL ACTIVITY TOGETHER WITH CROP TOLERANCE | RHONE-POULENC AGRICULTURE LIMITED (GB) | 2001-11-27 | — | — | US | disclosed |
| EP-0674629-A1 | 4-BENZOYL ISOXAZOLES DERIVATIVES AND THEIR USE AS HERBICIDES | RHONE-POULENC AGRICULTURE LTD. (GB) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014782-A1 | 4-BENZOYL ISOXAZOLES DERIVATIVES AND THEIR USE AS HERBICIDES | RHONE-POULENC AGRICULTURE LTD. (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045551-A1 | 4-benzoyl isoxazoles derivatives and their use as herbicides | CBR3, CBR1, GLRA3 | MEN1 4809/4885KMT2A 3499/4885TMEM97 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.